HT942526PCRPEIRA_GG.pdf

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Program Announcement for the Defense Health Agency

Prostate Cancer Research Program

Early Investigator Research Award

Funding Opportunity Number: HT942526PCRPEIRA

Pre-Application Due: August 12, 2026

Application Due: September 2, 2026 https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01

FY26 Prostate Cancer Early Investigator Research Award 2

Content

Before You Begin 3

Basic Information Summarizes the funding opportunity, funding details, submission deadlines and review dates

Eligibility Details eligibility factors for the applicant organization and Principal Investigator

Program Description Describes the program mission and intent of the Early Investigator Research Award;

provides key award information and considerations; and outlines funding details

Application Contents Presents the two-step application process and instructions for preparing a pre-application and full application

Submission Requirements Provides locations for application packages, instructions for submitting pre-applications and full applications, and describes application verification

Application Review Information Outlines the processes for application compliance review, pre-application and full application selection/notification, and risk assessment. Also, details the review criteria for pre-application screening and both tiers of the CDMRP application review process – Peer Review and Programmatic Review

Federal Award Notices Outlines what a successful applicant can expect if recommended for funding

Post-Award Requirements References policy requirements for funded research; outlines reporting requirements and restrictions related to Principal Investigator changes and institutional award transfers

Other Information Outlines criteria for administrative actions including application rejection, modification, withdrawal and withhold

Appendix 1 Includes a checklist for all full application components to facilitate application submission

Appendix 2 Acronym List

FY26 Prostate Cancer Early Investigator Research Award 3

Before You Begin

• Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission. User registration for each of these websites can take several weeks or longer.

Each applicant must ensure their registrations are active and up to date prior to application preparation.

• Read this funding opportunity announcement in the order it is written before beginning to prepare application materials. It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.

• To support application preparation, additional resources are available including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click to be taken to additional guidance and instructions within the General Application Instructions (GAI).

eBRAP Help Desk

301-682-5507 help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726 International: 1-606-545-5035 support@grants.gov

Questions regarding Grants.gov registration and Workspace.

https://sam.gov/ https://ebrap.org/eBRAP/public/index.htm https://grants.gov/register https://cdmrp.health.mil/#:~:text=Frequently%20Asked%20Questions%20%C2%BB https://cdmrp.health.mil/#:~:text=Guide%20for%20Intragovernmental%20%26%20Intramural%20Applicants https://ebrap.org/eBRAP/public/Program.htm#:~:text=Journey%20of%20an,Tier%20Review%20Process mailto:help@eBRAP.org mailto:support@grants.gov https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01

Section Shortcuts Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 4

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Prostate Cancer Research Program (PCRP) Early Investigator Research Award (EIRA) supports prostate cancer research conducted by investigators in the early stages of their careers with guidance from an experienced mentor. All applications must address one of the FY26 PCRP Overarching Challenges.

Distinctive Features:

• Early-Career Investigator: Serves as the principal investigator. Includes investigators possessing a doctoral degree or equivalent with fewer than three years of postdoctoral research experience at the application submission deadline, excluding clinical residency or clinical fellowship training.

• Mentorship: Applications must include at least one mentor who demonstrates experience in prostate cancer research and successful mentorship.

• Researcher Development Plan: Applications must include a researcher development plan articulating an individualized strategy for acquiring necessary skills, competence, and expertise to complete the project and foster the Principal Investigator’s (PI’s) career development

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $8.82M to fund approximately 14 Early Investigator Research Award applications with total cost caps of $630,000 per award. The maximum period of performance is 3 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

• Pre-Application (Letter of Intent) Submission Deadline: 5:00 p.m. Eastern Time (ET), August 12, 2026

• Application Submission Deadline: 11:59 p.m. ET, September 2, 2026

• End of Application Verification Period: 5:00 p.m. ET, September 8, 2026

• Peer Review: November 2026

• Programmatic Review: March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526PCRPEIRA

Assistance Listing Number: 12.420

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 5

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.

2.1.2. Principal Investigator

Early-career investigators affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application, regardless of ethnicity, nationality or citizenship status. To qualify as an early-career investigator, by the application submission deadline, the investigator must:

• Possess a doctoral degree (including but not limited to Ph.D., M.D., O.T.D., D.S.W., Sc.D., or equivalent) and

• Have three years or less of postdoctoral research experience. Postdoctoral research experience is calculated from the date of doctoral degree conferral to the application submission deadline. For physician investigators (M.D., D.O., or equivalent), exclude time spent in clinical residency or clinical fellowship training that is not primarily research focused.

An investigator may be named as a PI on a single application to this program announcement. If an investigator is named multiple times as a PI, only the first application received will be accepted; additional applications will be administratively withdrawn.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible organizations, not to individuals. Refer to the GAI for additional recipient qualification requirements.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Content_Form_Full_App_Submission:~:text=pre%2Dapplication%20submission.-,Extramural%20Organization%3A,-A%20foreign%20or https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=Intramural%20DOW%20Organization%3A%20A%20subset%20of%20intragovernmental%20organizations%3B%20refers%20specifically%20to%20DOW%20organizations%2C%20including%20DOW%20laboratories%2C%20DOW%20military%20treatment%20facilities%2C%20and/or%20DOW%20activities%20embedded%20within%20a%20civilian%20medical%20center.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=APPENDIX%201-,RECIPIENT%20QUALIFICATION%20AND%20RESTRICTION%20INFORMATION,-A.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 6

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the Prostate Cancer Research Program (PCRP). The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the PCRP in 1997 to promote innovative research focused on eradicating prostate cancer. Appropriations for the PCRP from FY97 through FY25 totaled $2.445 billion. The FY26 appropriation is $75 million (M).

The PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; the next generation of prostate cancer investigators through mentored research; and resources that will facilitate translational research.

3.1. Intent of the Early Investigator Research Award

The FY26 PCRP Early Investigator Research Award (EIRA) supports prostate cancer-focused research opportunities for individuals in the early stages of their careers under the guidance of one or more designated mentors. This opportunity allows early-career investigators to develop a research project, investigate a problem or question in prostate cancer research, and further their intellectual development as prostate cancer researchers of the future. As the PI, the early-career investigator should write all application components for the FY26 PCRP Early Investigator Research Award with appropriate direction from the mentor(s).

3.1.1. Overarching Challenges for the EIRA

All applications must address one of the following FY26 PCRP overarching challenges:

• Improve overall health, wellness and survivorship for those impacted by prostate cancer

Applications should aim to accelerate knowledge that translates to improve overall health and survivorship for those impacted by prostate cancer, with the goal of enhancing quality of life, overall health and survival. emotional health, healthy aging, cause-specific survival, cognitive function and other aspects of survivorship. Areas of particular interest include:

○ Biological basis of prostate cancer and its treatments on quality of life

○ The mental and emotional health of patients and their families/caregivers

○ Identification of groups of patients and their families at high risk of detriments in health and well-being

○ Implementation of factors or interventions that improve access to evidence-based care, quality-of-life outcomes and overall health and wellness

• Develop new treatments or improve upon existing therapies to improve outcomes for patients with lethal prostate cancer

Applications must be directly related to prostate cancer with a high risk of death, including high-risk localized disease, regional disease and/or metastatic prostate cancer.

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 7

Treatments may address any stage in the continuum of care, including local therapies such as surgery or radiation designed to treat patients with a high risk of death from the disease.

Proposed treatments are highly encouraged to consider preserving patient quality of life and not focus only on survival outcomes.

Applications should not focus on active surveillance or low-risk to intermediate-risk prostate cancer. Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).

• Enhance clinical care for all patients with prostate cancer

*Special emphasis on high-risk groups

Applications must be directly relevant to better understanding and/or reduction of factors that impact a person, their family or their caregiver’s ability to prevent, detect, manage and survive prostate cancer.

Factors may include physical, mental or emotional health differences experienced primarily in populations at high risk for prostate cancer, including Service Members and Veterans.

• Define the biology of prostate cancer progression to lethal prostate cancer to reduce death

Applications must be directly related to high-risk, very high-risk and metastatic prostate cancer. The FY26 PCRP also strongly encourages research involving patient-derived materials or specimens related to ongoing or completed clinical trials.

Refer to the National Comprehensive Cancer Network guidelines for risk assessment definitions (https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf).

3.1.2. Key Elements for the EIRA

• Principal Investigator: As the PI of the application, the early-career investigator must exhibit strong potential for and commitment to pursuing a career as an investigator at the forefront of prostate cancer research; however, the PI need not have previous prostate cancer research experience. The PI must have three years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training) as of the application submission deadline.

• Mentor(s): Applications must include at least one mentor appropriate to the proposed research project who has experience in prostate cancer research and mentoring as demonstrated by a record of active funding, recent publications and successful mentorship.

The primary mentor can be a junior faculty member, in which case the PCRP encourages the PI to include a secondary mentor with a robust track record in prostate cancer research and mentorship. The selected mentor(s) should also demonstrate a clear commitment to the development of the PI toward independence as a prostate cancer researcher. Mentors will be considered “key” for purposes of prior approval. Requests for changes in mentors will require a statement addressing changes to the Researcher Development Plan, if applicable.

• Research Approach: Proposed research project must address one or more of the FY26 PCRP Overarching Challenges. The scientific rationale and experimental methodology should demonstrate in-depth analysis of the research problem presented. The application should articulate the feasibility of the research design, the proposed methods and a clear plan to achieve the proposed project goals. The PCRP encourages, but does not require, https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf https://www.nccn.org/patients/guidelines/content/PDF/prostate-advanced-patient.pdf

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 8 inclusion of preliminary data relevant to prostate cancer and the proposed project.

Any preliminary data provided should originate from the PI, mentor(s) or member(s) of the collaborating team. Additionally, application should include documentation supporting identified required resources. Research involving human subjects and human anatomical substances is permitted; however, prospective recruitment of human subjects and clinical trials are not allowed under this funding opportunity.

• Researcher Development Plan: The PI must outline an individualized, prostate cancer-focused researcher development plan, which should include a clearly articulated strategy for acquiring the necessary skills, competence and expertise that will enable the PI to successfully complete the proposed research project and foster the PI’s development as an independent prostate cancer researcher. The plan must clearly describe an environment appropriate to the proposed mentoring and research project, including any mitigation of deficiencies of resources and/or mentorship at the PI’s institution through collaboration(s) with other institutions. If the application proposes using resources at another institution to successfully complete the proposed project, then the PCRP strongly encourages designating a co-mentor at the collaborating institution.

• Impact: Applications must address and provide a solution to one or more of the FY26 PCRP Overarching Challenges. The application should clearly describe the potential impact of the research, both short-term and long-term, in addressing the FY26 PCRP overarching challenge(s). High-impact research will, if successful, significantly advance prostate cancer research and/or patient care.

3.1.3. Other Important Considerations for the EIRA

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Clinical trials are not allowed within this funding opportunity.

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the ARRIVE 2.0 guidelines.

Applications from investigators within the DOW and applications involving multidisciplinary collaborations among academia, industry, the DOW, the U.S. Department of Veterans Affairs (VA) and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, their Families and the American Public. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.

The following encouragement is broadly applicable across many CDMRP programs, including the PCRP, A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY26 PCRP priorities.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=or%20hardware%20procurement.-,Clinical%20Trial%3A,-As%20defined%20in https://arriveguidelines.org/arrive-guidelines https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 9

3.2. Funding Instrument

The funding instrument for awards made under the program announcement will be grants

(31 USC 6304).

3.3. Funding Details

Period of Performance: The maximum period of performance is 3 years.

Cost Cap: The application’s total costs budgeted for the entire period of performance should not exceed $630,000. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization’s negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization’s negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum 3 years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

Direct Cost Restrictions: For this award mechanism, direct costs:

May be requested for (not all-inclusive):

• Workshop costs.

• Travel in support of multi-institutional collaborations.

• Costs for one investigator to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY26 PCRP Early Investigator Research Award.

• Clinical research costs.

Must not be requested for:

• Costs for travel to scientific/technical meeting(s) beyond the limits stated above.

• Clinical trial costs.

• Equipment.

• Salary support for the mentor(s) or any other senior/key personnel except the PI.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=Period%20of%20Performance%3A%20The%20time%20interval%20between%20the%20start%20of%20a%20federal%20award%20and%20the%20planned%20end%20date.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=in%20project%20activities.-,Cost%20Cap%3A,-The%20maximum%20cost

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 10

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a pre-application submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a full application submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

Pre-application submissions must include the following components.

LOI (one-page limit): Provide a brief description of the research to be conducted. Include the FY26 PCRP Overarching Challenge the research will address.

4.3. Full Application Components

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form (Grants.gov submissions only):

IMPORTANT: When completing the SF424 R&R, enter the eBRAP log number assigned during pre-application submission into Block 4a – Federal Identifier.

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

○ Attachment 1: Project Narrative (six-page limit): Upload as “ProjectNarrative.pdf”.

Describe the proposed project in detail using the outline below.

The Project Narrative must be written by the PI while also showing evidence of appropriate direction from the mentor(s).

– Principal Investigator: The application should describe the PI’s career goals, demonstrating a strong personal commitment to pursuing an independent career as a leader at the forefront of prostate cancer research. Describe how the proposed research project and mentoring experience will promote the PI’s development toward becoming an independent prostate cancer researcher. The application should discuss the PI’s research plans and career plans after the completion of this award.

– Mentor(s): Describe each mentor or co-mentor’s background and experience in prostate cancer research. Explain how the mentor(s) will assist the PI throughout the period of performance in developing toward independence in prostate cancer https://ebrap.org/eBRAP/public/index.htm https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=APPENDIX%202.%0AFORMATTING%20GUIDELINES https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=(a)%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20SF424%20(R%26R)%20%E2%80%93%20Application%20for%20Federal%20Assistance%20Form https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Project%20Narrative%3A,-Attach%20as%20%E2%80%9CProjectNarrative https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Full_App_Submission_Grants:~:text=IV.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20FULL%20APPLICATION%20SUBMISSION%20THROUGH%20GRANTS.GOV https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Full_App_Submission_eBRAP:~:text=V.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20FULL%20APPLICATION%20SUBMISSION%20THROUGH%20eBRAP

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 11 research. Provide details on the amount and types of interactions between the mentor(s) and the PI. Describe the track record of each mentor for mentoring early-career investigators in prostate cancer research. If the primary mentor is a junior faculty member, describe if a second mentor with a robust track record in prostate cancer research and mentorship will provide additional support for the PI and the proposed research project.

– Research Project: Describe the proposed research project, including the background, hypothesis/objective, specific aims, experimental design, methods and analyses, including the appropriate controls. The application must provide a sound scientific rationale for the proposed project and its feasibility as established through a critical review and analysis of published literature and/or logical reasoning.

Preliminary data are not required, but may be included to support the scientific rationale and feasibility of the research approaches. Any preliminary data provided should originate from the PI, mentor(s) or member(s) of the collaborating team. Address potential problem areas and present alternative methods and approaches. Include a statistical analysis plan for the proposed research, and a power analysis to support the design and sample size (if applicable).

Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported. Explain how cell line authentication and/or statistical rigor of preclinical experiments have been incorporated into the study design, if applicable. For clinical research, see Attachment 9 for the required strategy for the inclusion of women and minorities appropriate to the objectives of the study.

– Overarching Challenges: Briefly describe how the proposed research will help address and provide a solution to one or more of the FY26 PCRP Overarching Challenges.

If the proposed research involves access to military and/or VA patient populations and/or DOW or VA resources or databases, describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Also include a plan for obtaining any required data sharing, memorandum of understanding or other agreements required to access and publish data. Refer to the GAI, Appendix 4, for additional considerations.

○ Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

References Cited: List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

List of Abbreviations, Acronyms and Symbols: Provide a list of abbreviations, acronyms and symbols.

Facilities, Existing Equipment and Other Resources: Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=considered%20clinical%20trials.-,Clinical%20Research,-%3A%20For%20the https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Use_Of_DOW_Dept_Veterans_Affairs_Resource:~:text=APPENDIX%204.%0AUSE%20OF%20DOW%20OR%20U.S.%20DEPARTMENT%20OF%20VETERANS%20AFFAIRS%20RESOURCES https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Supporting%20Documentation%3A,-Combine%20and%20attach

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 12 equipment items are now accountable. There is not a standardized form for this information.

Publications and/or Patents: Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.

Letters of Support:

▪ Letter(s) from the Mentor(s): Provide letter(s) of recommendation from the mentor(s).

▪ Letters(s) of Collaboration: Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work.

▪ Letter(s) Signifying Access: If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.

Research Sharing Plan: Describe the type of data or research resources (e.g., bio-specimen, analysis tool/software, training material) to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived, if applicable. Identify and provide the rationale for any data or resources that will not be shared (e.g. for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

Intellectual Property Plan (if applicable): Provide a plan for resolving intellectual and material property issues among participating organizations.

Do not submit a copy of the National Institutes of Health Data Management and Sharing Plan or duplicate the Data Management Plan, which will be requested only after a recommendation for funding is made.

Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP’s expectations for making data and research resources publicly available.

https://ebrap.org/eBRAP/public/Program.htm#:~:text=Directive%20on%20Sharing%20Data%20and%20Research%20Resources

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 13

○ Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.

Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

Background: Present the scientific rationale behind the proposed research project.

Hypothesis/Objective(s): State the hypothesis to be tested and/or objective(s) to be reached.

Specific Aims: State the specific aims of the study.

Study Design: Describe the study design, including appropriate controls.

Military Relevance: Describe how the study is relevant to military health.

– Personnel: Describe the following:

▪ The PI’s career goals and potential for a career at the forefront of prostate cancer research.

▪ The strategy for acquiring necessary skills, competence, and expertise to successfully complete the proposed research project.

▪ The mentor’s (and co-mentor’s, if applicable) background and experience in prostate cancer research and proposed contribution to the career development of the PI.

▪ How the proposed research project will prepare the PI for a career at the forefront of prostate cancer research.

Impact: Summarize how the proposed research will address and provide a solution to one or more of the FY26 PCRP Overarching Challenges and ultimately provide progress toward eliminating death and suffering from prostate cancer and enhancing the well-being of Service Members and their Families, Veterans, and all the patients and caregivers experiencing the impact of the disease.

○ Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.

The lay abstract should address the points outlined below in a manner that is readily understood by readers without a background in science or medicine. Avoid overuse of scientific jargon, acronyms and abbreviations. Do not duplicate the technical abstract.

– Summarize the objectives and rationale for the proposed research.

– What are the likely contributions of this study to the FY26 PCRP Overarching Challenges?

– What population will the research help, and how will it help them?

– What are the potential applications, benefits and risks of the anticipated outcomes?

– What are the likely contributions of the proposed research project to advancing research, patient care and/or quality of life?

– What is the potential benefit of the proposed study and the anticipated outcomes to Service Members, Veterans and/or their Families?

– Describe the PI’s career goals in prostate cancer research and patient care.

https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Lay%20Abstract%3A,-Attach%20as%20%E2%80%9CLayAbs https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Technical%20Abstract%3A,-Attach%20as%20%E2%80%9CTechAbs

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 14

▪ How does the research plan support the PI in achieving these goals?

▪ How do the mentorship and researcher development plan support the PI in achieving these goals?

○ Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.

Refer to eBRAP for the Suggested SOW Format.

For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

○ Attachment 6: Researcher Development Plan (two-page limit): Upload as “ResearchDev.pdf”.

– Clearly articulate an individualized strategy that will enable the PI to acquire the necessary skills, competence and expertise to successfully complete the proposed research project.

– Indicate how the individualized researcher development plan will provide the PI with an opportunity to develop a research project, investigate a problem or question in the field of prostate cancer and effectively prepare the PI for a career as an independent prostate cancer researcher.

– Describe how the researcher development plan is supported by the environment and mentorship, including a description of ongoing prostate cancer research at the institution. Include a description of the environment of any collaborating institutions that will augment the lack of specific resources at the PI’s primary institution (if applicable). If the PI will be utilizing resources at another institution to successfully complete the proposed project, then the PI is strongly encouraged to designate a co-mentor at the collaborating institution. Include information on collaborations with other investigators, seminars, workshops and other opportunities for professional interaction with leaders in the prostate cancer field. The application cannot involve members of the FY26 PCRP Programmatic Panel.

○ Attachment 7: Impact Statement (one-page limit): Upload as “Impact.pdf”.

– Describe the short-term impact: Detail the anticipated outcome(s)/product(s) that will be directly attributed to the results of the proposed research, including any clinically relevant results. Summarize how the anticipated outcome(s)/product(s) address(es) and will help provide a solution to one or more of the FY26 PCRP Overarching Challenges.

– Describe the long-term impact: Explain the anticipated long-term gains from the proposed research, including the anticipated advantages that the new understanding may contribute to the goal of elimination of death and suffering from prostate cancer.

– Describe the relevance to military health: Briefly describe how the proposed research is relevant to Service Members, Veterans and/or their Families.

○ Attachment 8: Eligibility Statement (one-page limit): Upload as “Eligibility.pdf”.

Provide a letter, signed by the PI and the Department Chair, Dean or equivalent official, to verify that the eligibility requirements have been met by the application submission deadline. The letter should provide the date (month/year) the PI completed/will complete requirements for their doctoral degree, and the date (month/year) the PI began/will begin postdoctoral research (excluding clinical residency or fellowship) in the proposed setting.

https://ebrap.org/eBRAP/public/Program.htm#:~:text=Suggested%20SOW%20Format https://ebrap.org/eBRAP/public/Program.htm#:~:text=Example%3A%20Assembling%20a%20Clinical%20Research%20and/or%20Clinical%20Trial%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:~:text=Example%3A%20Assembling%20a%20Clinical%20Research%20and/or%20Clinical%20Trial%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:~:text=Example%3A%20Assembling%20a%20Generic%20Statement%20of%20Work https://ebrap.org/eBRAP/public/Program.htm#:~:text=Example%3A%20Assembling%20a%20Generic%20Statement%20of%20Work https://cdmrp.health.mil/pcrp/panels/PCRP%20FY26%20Programmatic%20Panel%20List.pdf https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=%C2%B7-,Statement%20of%20Work%3A,-Attach%20as%20%E2%80%9CSOW

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 15

○ Attachment 9: Inclusion of Women and Minorities (four-page limit): Upload as “Inclusion.pdf”. (Attachment 9 is only applicable and required for applications that propose clinical research.) Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial and ethnic group, and an accompanying rationale for the selection of subjects. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. The “Public Health Service (PHS) Inclusion Enrollment Report” is a three-page fillable PDF form, that can be downloaded from eBRAP.

○ Attachment 10: Transition Plan (one-page limit): Upload as “Transition.pdf”.

Provide information on potential methods and strategies to move the project’s findings to the next phase of development, clinical trials, and/or delivery to the commercial market after successful completion of the award (e.g., specific potential industry partners, specific funding opportunities to apply for). Provide a realistic timeline for near-term clinical investigation. In addition, provide a plan to distribute the findings or intervention to the prostate cancer community.

○ Attachment 11: Representations (Grants.gov submissions only): Upload as “RequiredReps.pdf”. All extramural applicants must complete and submit the Required Representations document available on eBRAP.

○ Attachment 12: Suggested Intragovernmental/Intramural Budget Form (if applicable): Upload as “IGBudget.pdf”. If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

i. Research & Related Senior/Key Person Profile (Expanded)

○ Biographical Sketch

○ Current/Pending Support

Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) (if applicable, Grants.gov submissions only)

External Link to the GAI

Grants.gov

External Link to the GAI eBRAP.org https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=considered%20clinical%20trials.-,Clinical%20Research,-%3A%20For%20the https://ebrap.org/eBRAP/public/Program.htm#:~:text=Statement%20of%20Work-,Public%20Health%20Service%20Inclusion%20Enrollment%20Report,-n/a https://ebrap.org/eBRAP/public/Program.htm#:~:text=Required%20Representations https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Definition_List:~:text=Intramural%20DOW%20Organization%3A%20A%20subset%20of%20intragovernmental%20organizations%3B%20refers%20specifically%20to%20DOW%20organizations%2C%20including%20DOW%20laboratories%2C%20DOW%20military%20treatment%20facilities%2C%20and/or%20DOW%20activities%20embedded%20within%20a%20civilian%20medical%20center.

https://ebrap.org/eBRAP/public/Program.htm#:~:text=Suggested%20Intragovernmental/Intramural%20Budget https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=B.%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%C2%A0%20Representations https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Recipient_Qualification_Restriction_Info:~:text=Suggested%20Intragovernmental/Intramural%20Budget%20Form%2C%20if%20applicable%3A https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Additional_App_Materials_IV:~:text=C.-,Additional%20Application%20Materials,-The%20following%20are https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Additional_App_Materials_V:~:text=B.-,Additional%20Application%20Materials,-The%20following%20are

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 16

4.4. Other Application Elements

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

https://www.esd.whs.mil/Portals/54/Documents/DD/issuances/dodi/320012p.pdf?ver=2018-12-17-130508-423 https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Additional_App_Materials_V:~:text=E.-,DOW%20Data%20Management%20Plan,-If%20recommended%20for

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 17

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526PCRPEIRA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow

5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI through eBRAP.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization and contracting organization must be consistent throughout the entire https://grants.gov/ https://ebrap.org/eBRAP/public/Program.htm https://www.sam.gov/content/home https://ebrap.org/ https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_Additional_App_Materials_V:~:text=Obtain%20Unique%20Entity%20Identifier%20from%20System%20for%20Award%20Management https://ebrap.org/eBRAP/public/gai.htm?version=CD26_01#_PreApp_Submission:~:text=III.-,PRE%2DAPPLICATION%20SUBMISSION,-General%20information%20about

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements

Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

FY26 Prostate Cancer Early Investigator Research Award 18 pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP.

Contact the eBRAP Help Desk if any changes need to be made.

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations must be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to…